layer1-background

News

 
News
  Date Title View
May 26, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 26, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Gaurav Aggarwal, M.D., Chief Business Officer, will be presenting at the 2016 BIO International Conven...
Apr 29, 2016
-- Company on target to complete enrollment in STOP-HE in the fourth quarter; approximately 165 patients enrolled to date -- -- Study with orally-available OCR-002 in patients with cirrhosis to begin in the third quarter with data expected by year-end -- PALO ALTO, Calif. an...
Apr 15, 2016
Data establish ammonia-lowering properties of orally-administered OCR-002 in preclinical model of cirrhosisData highlight CNS neurochemical changes occurring in preclinical model of hepatic encephalopathy which are normalized with OCR-002 PALO ALTO, Calif. and...
Apr 11, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 11, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the publication of promising preclinical data related to the Company's investigational drug candidate orn...
Apr 5, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 05, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the 15th Annual Needham...
Mar 3, 2016
-- Patient enrollment progressing in STOP-HE clinical trial of OCR-002; Company expects to complete enrollment in the fourth quarter of 2016 -- -- OCR-002 is the only ammonia scavenger in development for both treatment and prevention of hepatic encephalopathy (HE) -- PALO ALTO, Ca...
Feb 29, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the Cowen and Company 36th...
Feb 2, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that the Company will be presenting at the 18th Annual BIO CEO & Investor Conference taking pla...
Jan 8, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced further details from its Phase 1 study of oral formulations of OCR-002, ornithine phenylacetate, in health...
Jan 7, 2016
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Dr. Stan Bukofzer as Chief Medical Officer. Dr. Bukofzer most recently served as Chief ...
1
...
NextLast
= add release to Briefcase